BALT Appoints Pascal Girin As CEO Of BALT International

Nicolas Plowiecki, President of BALT and its Board of Directors, chaired by Oern Stuge, has hired Medical Devices veteran Pascal Girin to guide the group in its growth path and development efforts.

Pascal has spent most of his career in the Medical Devices sector and has an in-depth expertise of the Interventional Neuroradiology industry. Indeed from 2003 to 2010, he acted as President Europe, President International, Executive Vice President and President, in charge of the worldwide neurovascular activities and COO at ev3 (sold to Covidien in 2010). He also worked as VP Europe at Baxter, CEO of Keystone Dental and most recently, COO for Wright Medical Technology.

BALT will continue to focus on accompanying practitioners through further innovation to treat complex life-threatening conditions. The appointment of Pascal is meant to bolster the commercial and market access capabilities of Balt and lead its expansion in the US market.

“I am pleased to welcome Pascal in the team. We have known and respected each other for a decade and I am sure that Pascal will perfectly fit with the culture of the Group” says Nicolas Plowiecki. “The Neurovascular industry is facing an unprecedented level of innovation and growth. Pascal comes with tremendous strategic and industry experience to guide the group’s development across the world, giving it the means to address the strong demand from our customers.”

“Thanks to the quite unique innovation DNA of the founding family, BALT has the best and widest product range in the sector” adds Pascal Girin, new CEO of BALT International. “Our duty is to bring BALT’’s products to practitioners across the globe, allowing them to treat ever more complex cases. I am very enthusiastic about the growth potential of the group.”

Through this new recruitment, Bridgepoint, shareholder of BALT since September 2015 alongside the founding family, reaffirms its strong support and ambition for the group.

About BALT
Since it was established in 1977, BALT has worked with neurovascular surgeons to treat complex life-threatening conditions such as strokes, aneurysms and arteriovenous malformations. A pioneer in its field, BALT designs, manufactures and distributes the 'Interventional Neuro Radiology’ (‘INR’) devices such as catheters, stents and coils that are essential in treating such conditions. BALT is one of the leading pure play MedTech companies in Europe, and is a supplier to all major French and international hospitals practicing neuroradiology surgery. Headquartered in France, it boasts a number of proprietary, patent-protected products focusing on minimally invasive neurovascular techniques. In 2015, the company produced over 16,000 medical devices and generated revenues of €100 million, 95% of which are generated outside France via its own sales network and over 100 distributors worldwide.